High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial tests how well radiation therapy with pembrolizumab and chemotherapy (paclitaxel or nab-paclitaxel or carboplatin and gemcitabine) works in treating patients with PD-L1 positive triple negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work better than other forms of paclitaxel. Carboplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill cancer cells. High dose radiation therapy with pembrolizumab and chemotherapy may effective in treating patients with PD-L1 positive metastatic triple negative breast cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony biopsją rak piersi z przerzutami, oporny na hormonalne leczenie, z wynikiem dodatnim na PD-L1 i co najmniej 2 widocznymi ogniskami przerzutów w badaniach obrazowych
- •Wynik dodatni na PD-L1 potwierdzony testem Dako 22c3 (wynik ≥ 10)
- •Badanie fizykalne i historia choroby wykonane w ciągu 60 dni przed włączeniem do badania
- •Tomografia komputerowa klatki piersiowej, brzucha i miednicy oraz badania scintigraficzne lub PET-CT wykonane w ciągu 4 tygodni przed rozpoczęciem radioterapii
- •Zaliczenie przez lekarza do radioterapii
- •Zaliczenie przez lekarza do immunoterapii i chemioterapii taksanami
- •Co najmniej jedno ognisko przerzutu nadające się do wysokodawkowej radioterapii
- •Wiek co najmniej 18 lat
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- April 17, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Emory University Hospital/Winship Cancer Institute
Atlanta, United States
Trial contact
Manali Bhave, MD
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.